Shrey Velani, MD
Pulmonary Disease · Des Moines, IANPI 1699020933
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $13,130 of the $17,949 with a category attached, or 73.2%. Intuitive Surgical accounts for 95.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $10,039 and has fallen 95.4% since, to $459 in 2025. Among pulmonary disease clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 92 payments — averaging $195.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$17K
- Penumbra, Inc.$209
- AstraZeneca$125
- La Jolla Pharmaceutical Company$105
- GSK$74
- Conmed Corporation$63
- plus $285 from 8 others
What the payments were for
- Travel & lodging$13,13073%
- Food & beverage$1,6819%
- Education$3,00017%
- Gifts$1371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 75 | $17,087 |
| Penumbra, Inc. | 1 | $209 |
| AstraZeneca | 1 | $125 |
| La Jolla Pharmaceutical Company | 1 | $105 |
| GSK | 3 | $74 |
| Conmed Corporation | 1 | $63 |
| ERBE USA Inc | 1 | $56 |
| Amgen | 2 | $48 |
| Galvanize Therapeutics, Inc | 1 | $38 |
| Insmed, Inc. | 2 | $37 |
| Davol Inc. | 1 | $33 |
| Abiomed | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$15,970
- Indigo$209
- TAGRISSO$125
- GIAPREZA$105
How this compares
$17,949 in reported general payments places this provider in the 90th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 13 | $58,306 |
| Breo ElliptaFluticasone/Vilanterol | 129 | $51,322 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $49,427 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $33,514 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 56 | $29,203 |
| Spiriva RespimatTiotropium Bromide | 45 | $23,548 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 28 | $11,774 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $7,892 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $6,495 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $6,374 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $5,548 |
| DuleraMometasone/Formoterol | 16 | $5,426 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $2,346 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $2,217 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $1,772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $74 | $135,501264 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Bevespi Aerosphere, Symbicort | $125 | $109,967111 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $16 | $31,44062 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in Des Moines
- Neil HorningDes Moines$15K
- Jason WittmerDes Moines$10K
- Bradley WilcoxDes Moines$7K
- Blair WesterlyDes Moines$7K
- Eric AsbeDes Moines$4K
- Maxwell CosmicDes Moines$3K
- Anthony GrecoDes Moines$3K
- Lucas Silqueira Hickson CruzDes Moines$2K
- Maksym PuliaievDes Moines$2K
- Bryon JohnsonDes Moines$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.